IRIS
BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.772
NA - Nord America 1.368
AS - Asia 354
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 2
AF - Africa 1
Totale 3.512
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.360
IE - Irlanda 939
SE - Svezia 304
IT - Italia 205
UA - Ucraina 198
SG - Singapore 186
HK - Hong Kong 112
DE - Germania 43
VN - Vietnam 31
FR - Francia 24
BE - Belgio 19
EU - Europa 15
CA - Canada 8
FI - Finlandia 8
RO - Romania 8
GB - Regno Unito 7
IN - India 7
IR - Iran 6
CZ - Repubblica Ceca 5
NL - Olanda 3
PH - Filippine 3
BG - Bulgaria 2
CH - Svizzera 2
IL - Israele 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
CN - Cina 1
CO - Colombia 1
EG - Egitto 1
JP - Giappone 1
KG - Kirghizistan 1
LT - Lituania 1
MK - Macedonia 1
NO - Norvegia 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 3.512
Salva come PNG Salva come JPEG
Città #
Dublin 925
Jacksonville 371
Singapore 135
Wilmington 119
Lawrence 118
Princeton 118
Hong Kong 112
Chandler 108
San Mateo 106
Ashburn 35
Dong Ket 30
Piemonte 26
Ann Arbor 25
Boardman 23
Munich 19
Brussels 18
Santa Clara 15
Norwalk 14
Houston 10
Turin 10
Andover 8
Helsinki 8
Milan 7
Novara 7
Toronto 7
Fairfield 6
Horia 6
West Jordan 6
Woodbridge 6
Brno 5
Grafing 5
Mülheim 5
Naples 5
Palermo 5
San Diego 5
Seattle 5
Alessandria 4
Cambridge 4
Leawood 4
Rome 4
Torino 4
Amsterdam 3
Bremen 3
Monmouth Junction 3
Paris 3
Pioltello 3
Sant'Anastasia 3
Strasbourg 3
Trivero 3
Appiano Gentile 2
Atripalda 2
Bagnoli del Trigno 2
Bucharest 2
Bulandshahr 2
Busalla 2
Caloocan City 2
Canegrate 2
Des Moines 2
Giugliano In Campania 2
Kolkata 2
Los Angeles 2
Messina 2
Napoli 2
Nottingham 2
Philadelphia 2
Redwood City 2
Romainville 2
Saint-Fons 2
Senago 2
Vercelli 2
Zanjan 2
Alba 1
Ardabil 1
Augusta 1
Berlin 1
Bishkek 1
Bogotá 1
Boltiere 1
Buenos Aires 1
Cairo 1
Casavatore 1
Cassano Magnago 1
Castelli Calepio 1
Cologno Monzese 1
Dhaka 1
Elk Grove Village 1
Erba 1
Falconara Marittima 1
Filottrano 1
Forest City 1
Fremont 1
Genova 1
Giarre 1
Ho Chi Minh City 1
Jerusalem 1
Kish 1
Kuesnacht 1
La Canada Flintridge 1
London 1
Magreglio 1
Totale 2.550
Salva come PNG Salva come JPEG
Nome #
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 145
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 104
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 95
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 58
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir 51
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 51
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 48
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 47
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 45
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 45
Ceftobiprole perspective: Current and potential future indications 43
Prevalenza e fattori di rischio dell'insorgenza di psicosi acuta 59 nei pazienti anziani ospedalizzati per infezione da Sars-COV-2: studio retrospettivo 43
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 40
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 38
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 37
Coinfection with other respiratory pathogens in COVID-19 patients 37
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 36
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 36
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 36
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy 36
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 34
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 34
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 34
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 33
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients 33
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 33
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 33
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis 32
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 32
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 31
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 31
Combination therapy in chronic hepatitis B: what are the real benefits? 31
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir 31
Lo studio filologico applicato alla descrizione della “pestilenza” di Atene di Tucidide: dall’analisi del testo agli aspetti di epidemiologia e malattie infettive 31
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 30
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 30
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon] 30
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 30
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis 30
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 29
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? 29
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 29
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 28
Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir 28
Le coinfezioni in epatologia 28
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 27
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 27
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 27
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 27
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 27
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 27
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 27
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 27
Interazioni farmacologiche nel paziente con infezione da HCV 27
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 26
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 26
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools 26
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 26
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 26
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 26
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection 26
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 26
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 25
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 25
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes 25
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 25
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms 25
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 25
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 25
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers 25
Letter: liver involvement and mortality in COVID-19—the role of anti-viral therapy should be considered 25
The Role of IL28B Genotype in HCV-RNA Baseline Levels 25
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 24
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 24
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 24
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 24
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 24
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 24
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 24
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 24
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 24
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E 24
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 24
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 23
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 23
Klebsiella pneumoniae meningitis in a 38-year-old Chinese traveller with impaired glucose tolerance: A new emerging syndrome? 23
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 23
Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience 23
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis 23
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 23
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 23
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 23
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 23
Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? 23
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 22
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes 22
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 22
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 22
Influenza della somministrazione del metadone sulle concentrazioni plasmatiche di daclatasvir in una coorte di pazienti con epatite cronica da HCV e tossicodipendenza attiva 22
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia 22
Totale 3.195
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.113
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202093 0 0 0 0 0 0 0 0 0 0 0 93
2020/2021672 92 0 92 8 98 15 102 10 102 4 109 40
2021/2022673 8 10 126 47 20 21 27 16 93 24 120 161
2022/20231.564 135 111 89 24 36 89 33 61 913 13 44 16
2023/2024441 26 19 18 9 64 6 116 15 13 10 7 138
2024/2025212 14 11 100 25 14 48 0 0 0 0 0 0
Totale 3.655